For UK HealthTech companies
NHS buyers won't engage with a supplier they've never heard of
Without published clinical content, speaking slots, or peer endorsement, your team arrives at every conversation from a standing start. Risk-averse procurement teams consistently favour the name they already recognise.
Two minutes. Solva follows up with specific content and positioning options.
- Healthtech sales teams facing constant rejections or being unable to get past gatekeepers in NHS trusts and ICBs
- Products being overlooked in tender processes despite offering superior technical features
- Lack of invitations to participate in pilot programs or innovation showcases within the NHS
- Difficulty in securing speaking slots at influential healthcare conferences or gaining media coverage in key sector publications
- Inefficient sales cycles with high resource expenditure and low conversion rates
- Increased reliance on cold outreach and generic marketing campaigns that yield poor ROI
- Reduced revenue growth and market share within the lucrative NHS sector
- Higher customer acquisition costs due to prolonged sales cycles and ineffective marketing
- Perception as a transactional vendor rather than a trusted partner or innovator
- Limited brand recognition and credibility within the UK healthcare community
No verified UK data available
Source: No verified UK data available
Frequently asked questions
Why does this problem persist?
NHS buyers are risk-averse and rely on peer recommendation and visible expertise before engaging with a supplier. Without published content, conference speaking slots, or clinical champion networks, healthtech companies remain invisible to the stakeholders who matter most.
What is the cost of leaving it unaddressed?
No verified UK data available
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.